The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

The fully implanted Acclaim® cochlear implant received Breakthrough Device Designation from the FDA in 2019 and was first implanted in three participants during an early feasibility study (EFS) at ...

Each study randomized three patients to a treatment group for every control, leading to approximately 120 ALS patients ...

Conformal Medical today announced on social media that the first U.S. site enrolled a patient in a trial of its next-gen ...

Imunon (IMNN) announced new translational data from ongoing analyses of results from the Company’s Phase 2 OVATION 2 Study of IMNN-001, its ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...